Lorazepam (Ativan) is preferred over midazolam for initial IV treatment of breakthrough seizures in a 3-year-old child
For status epilepticus in pediatric patients with IV access available, lorazepam should be administered as the first-line benzodiazepine. 1 The American Academy of Pediatrics guidelines explicitly state that "other benzodiazepines (eg, lorazepam) are typically used for initial IV treatment of status epilepticus" when comparing to midazolam 1.
Evidence Supporting Lorazepam as First-Line
The 2008 AAP Pediatrics guidelines provide clear dosing: lorazepam 0.05–0.10 mg/kg IV (maximum 4 mg per dose), repeatable every 10–15 minutes if seizures continue 1. This recommendation is reinforced across multiple guideline sources 1.
Lorazepam has a longer duration of anticonvulsant activity compared to midazolam and diazepam, which is clinically significant because it reduces seizure recurrence within the critical 15-20 minute window 1. The WHO guidelines for low- and middle-income countries also establish IV lorazepam as preferred when IV access is available 2.
Network meta-analysis data shows that IV lorazepam has the highest probability (SUCRA = 0.4346) of being the best treatment for reducing respiratory depression among benzodiazepines, while maintaining comparable efficacy to midazolam 3. A 2016 systematic review confirmed that IV lorazepam and IV diazepam are established as Level A evidence for efficacy in children with seizures lasting at least 5 minutes 4.
When Midazolam is Appropriate
Midazolam becomes the preferred agent when IV access is NOT available. The guidelines specify IM midazolam 0.2 mg/kg (maximum 6 mg) for this scenario 1. For refractory status epilepticus not controlled by standard therapies, midazolam can be used as a continuous infusion (loading dose 0.15–0.20 mg/kg, followed by 1 mg/kg per min titrated up to 5 mg/kg per min) 1.
The 2019 CAR T-cell therapy guidelines recommend lorazepam 0.1 mg/kg (maximum 2 mg) IV for convulsive status epilepticus, repeatable after at least 1 minute to a maximum of 2 doses 5. For non-convulsive status epilepticus, they recommend lorazepam 0.05 mg/kg (maximum 1 mg) IV, repeatable every 5 minutes up to 4 doses 5.
Critical Dosing Considerations
A major pitfall is underdosing benzodiazepines. Recent data shows 43.4% of EMS-provided initial benzodiazepine doses were inappropriately low 6. Underdosing is associated with need for multiple doses and treatment failure 7, 6.
For a 3-year-old (average weight ~15 kg):
- Lorazepam: 0.75–1.5 mg IV (0.05–0.10 mg/kg)
- Midazolam IM (if no IV): 3 mg (0.2 mg/kg)
Safety Profile
Both medications carry risk of respiratory depression, but this risk is lower with benzodiazepine treatment than with untreated status epilepticus 4. The FDA label for Ativan notes that while safety in pediatric status epilepticus has not been formally established in controlled trials, a randomized trial comparing lorazepam to diazepam in 273 pediatric patients (ages 3 months to 17 years) showed assisted ventilation was required in 18% of lorazepam patients versus 16% of diazepam patients 8.
Common adverse effects include sedation (67% with lorazepam), respiratory depression, and paradoxical excitation in 10-30% of children under 8 years 8. Equipment for airway management must be immediately available 8.
Important Caveats
Benzyl alcohol warning: Ativan Injection contains benzyl alcohol, which has been associated with "gasping syndrome" in neonates at doses >99 mg/kg/day. While therapeutic doses are substantially lower, premature and low-birth-weight infants may be at higher risk 8.
Seizure activity and myoclonus have been reported following lorazepam administration, especially in very low birth weight neonates 8.
The 2023 ILAE neonatal seizure guidelines note that for neonates specifically, phenobarbital remains first-line regardless of etiology, with phenytoin or levetiracetam as second-line 9.